Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Indivior (NASDAQ/LSE: INDV) has appointed Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Procter brings 25 years of biopharmaceutical industry experience and will oversee Corporate Communications, Government Affairs, Policy and Advocacy.
Prior to joining Indivior, Procter served as Senior Vice President of Corporate Affairs at Sage Therapeutics, where she led the successful launch of ZURZUVAE™. She previously held leadership positions at Alexion Pharmaceuticals and MedImmune, and worked as a health policy advisor in the U.S. House of Representatives.
Details
News Market Reaction – INDV
The recorded move for INDV in the trading session of this news was -2.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
"We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to priorities and executing successful multi-stakeholder strategies that drive patient access in complex regulatory environments. We look forward to her expertise and invaluable contributions as we pursue our mission to transform the lives of people living with opioid use disorder."
"I am honored to join Indivior at this transformative time for the Company," said Ms. Procter. "Public policy and community engagement are critical to address this significant public health challenge; providing the framework, funding and systems necessary to ensure treatment in the right place and at the right time. I look forward to working with the Indivior team and deepening our engagement with the people and communities we serve to further this important work."
Ms. Procter brings 25 years of experience in the biopharmaceutical industry, having led corporate and government affairs for multiple organizations. Most recently, Ms. Procter was Senior Vice President of Corporate Affairs at Sage Therapeutics, where she led a team that conditioned the environment for the successful product launch of ZURZUVAE™, the first pill for post-partum depression. In that role, she led corporate communications, investor relations, government affairs and patient advocacy. Prior to her time at Sage, she was Head of
Ms. Procter earned her B.A. in History from Gettysburg College.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-appoints-vanessa-procter-as-executive-vice-president-of-corporate-affairs-302499820.html
SOURCE Indivior PLC
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.